Screener
Tandem Diabetes Care TNDM Payments to Acquire in Process Research and Development
Payments to Acquire in Process Research and Development at other companies
Other financials
Where this comes from
Reported directly by Tandem Diabetes Care in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment.
The source filing: Tandem Diabetes Care’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001438133-26-000125
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Purchases of short-term investments | (260,512) | (26,496) |
| Proceeds from maturities and redemptions of short-term investments | 69,473 | 146,447 |
| Purchases of property and equipment | (10,318) | (9,171) |
| Acquisition of in-process research and development | — | (43,464) |
| Purchases of equity investments, strategic investments, and intangible assets | (81,427) | — |
| Net cash provided by (used in) investing activities | (282,784) | 67,316 |
| Financing Activities | ||
| Proceeds from issuance of convertible senior notes due 2032, net of $8,843 debt issuance costs | 291,157 | — |
Item 1. Financial Statements.
FAQ
- What is Tandem Diabetes Care's payments to acquire in process research and development?
- Tandem Diabetes Care (TNDM) reported payments to acquire in process research and development of $0 in Q2 2026.
- What does payments to acquire in process research and development mean?
- Payments to Acquire in Process Research and Development
Ask your AI about Tandem Diabetes Care's payments to acquire in process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude